Global X Genomics & Biotechnology ETF (GNOM)
11.84
-0.16
(-1.35%)
USD |
NASDAQ |
Mar 30, 14:08
Key Stats
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.50% | 0.02% | 194.80M | 80534.47 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0% | 39.39% | 58.01M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | Global X Funds |
| Prospectus Benchmark Index | |
| Solactive Genomics NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Nam To | 3.91 yrs |
| Wayne Xie | 3.91 yrs |
| Kimberly Chan | 3.73 yrs |
| Vanessa Yang | 2.16 yrs |
| Sandy Lu | 0.91 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
9
58.01M
-2.719B
Category Low
6.230B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 29, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 29, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| 10x Genomics Inc Ordinary Shares - Class A | 7.76% | 51.64 | 1.77% |
| Sarepta Therapeutics Inc | 5.16% | 136.06 | -0.37% |
| Natera Inc | 5.15% | 54.21 | -4.73% |
| Qiagen NV | 4.54% | 45.63 | -0.63% |
| Biomarin Pharmaceutical Inc | 4.37% | 95.15 | 1.01% |
| Agilent Technologies Inc | 4.25% | 134.25 | 0.30% |
| Bio-Techne Corp | 4.18% | 72.47 | 0.57% |
| Ultragenyx Pharmaceutical Inc | 4.15% | 37.81 | -3.22% |
| Alnylam Pharmaceuticals Inc | 4.14% | 194.99 | -0.47% |
| Illumina Inc | 3.98% | 222.19 | 0.07% |
News
Headline
Wire
Time (ET)
Basic Info
| Investment Strategy | |
| The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | Global X Funds |
| Prospectus Benchmark Index | |
| Solactive Genomics NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Nam To | 3.91 yrs |
| Wayne Xie | 3.91 yrs |
| Kimberly Chan | 3.73 yrs |
| Vanessa Yang | 2.16 yrs |
| Sandy Lu | 0.91 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-30-23) | 0% |
| 30-Day SEC Yield (3-27-23) | Upgrade |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of March 28, 2023
Fund Details
| Key Dates | |
| Inception Date | 4/5/2019 |
| Last Annual Report Date | 11/30/2022 |
| Last Prospectus Date | 4/1/2022 |
| Attributes | |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)